Shots:

• The CHMP’s recommendation is based on two P-III studies demonstrating the safety and efficacy of Supemtek (quadrivalent recombinant influenza vaccine) in 10-000+ patients aged ≥18yrs. The company expects EC’s decision in Q4’20
• Supemtek is the first and only influenza vaccine to rely on recombinant manufacturing technology and is available in the US since 2017
• Additionally- CHMP also recommends the approval of MenQuadfi for active immunization of individuals aged ≥ 12yrs. against invasive meningococcal ACWY disease with expected EC’s decision by the end of 2020

Source 1- Source 2 ­ Ref: Sanofi | Image: Campaign Asia